Chapters

Transcript

Video

How was IL-2 re-engineered to generate a cytokine fusion protein that selectively binds to the intermediate-affinity IL-2 receptor and activates antitumor cytolytic effector natural killer cells and CD8+ T cells while minimizing expansion of Tregs?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH